## Lionel Perrier,, Hdr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9330155/publications.pdf

Version: 2024-02-01

567281 642732 49 647 15 23 citations g-index h-index papers 59 59 59 1273 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	How We Can Reap the Full Benefit of Teleconsultations: Economic Evaluation Combined With a Performance Evaluation Through a Discrete-Event Simulation. Journal of Medical Internet Research, 2022, 24, e32002.	4.3	O
2	How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?. Bulletin Du Cancer, 2021, 108, 1170-1180.	1.6	7
3	Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health. Bulletin Du Cancer, 2021, 108, 1162-1169.	1.6	2
4	Connected device and therapeutic patient education to promote physical activity among women with localised breast cancer (DISCO trial): protocol for a multicentre 2Å—2 factorial randomised controlled trial. BMJ Open, 2021, 11, e045448.	1.9	1
5	Connected device and therapeutic patient education to promote physical activity among women with localised breast cancer (DISCO trial): protocol for a multicentre 2A—2 factorial randomised controlled trial. BMJ Open, 2021, 11, e045448.	1.9	4
6	Cost–Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review. Pharmacoeconomics, 2020, 38, 341-356.	3.3	7
7	Cost-effectiveness of an exercise and nutritional intervention versus usual nutritional care during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial. Supportive Care in Cancer, 2020, 28, 2829-2842.	2.2	11
8	A comparison of two modalities of stereotactic body radiation therapy for peripheral early-stage non-small cell lung cancer: results of a prospective French study. British Journal of Radiology, 2020, 93, 20200256.	2.2	5
9	Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments. Value in Health, 2020, 23, 898-906.	0.3	7
10	Chronic Low-Dose Exposure to Xenoestrogen Ambient Air Pollutants and Breast Cancer Risk: XENAIR Protocol for a Case-Control Study Nested Within the French E3N Cohort. JMIR Research Protocols, 2020, 9, e15167.	1.0	7
11	National costs and resource requirements of external beam radiotherapy: A time-driven activity-based costing model from the ESTRO-HERO project. Radiotherapy and Oncology, 2019, 138, 187-194.	0.6	36
12	Feasibility of an exercise and nutritional intervention for weight management during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial. Supportive Care in Cancer, 2019, 27, 3449-3461.	2.2	20
13	The contribution of genomics in the medicine of tomorrow, clinical applications and issues. Therapie, 2019, 74, 9-15.	1.0	4
14	In Reply to Daisne etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 100, 808-809.	0.8	0
15	Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study. European Journal of Human Genetics, 2018, 26, 314-323.	2.8	59
16	In Reply to Tallet etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 100, 529-530.	0.8	0
17	Performance and cost evaluation of health information systems using micro-costing and discrete-event simulation. Health Care Management Science, 2018, 21, 204-223.	2.6	14
18	The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group. PLoS ONE, 2018, 13, e0193330.	2.5	38

#	Article	IF	Citations
19	Systematic Screening for Occupational Exposures in Lung Cancer Patients: A Prospective French Cohort. International Journal of Environmental Research and Public Health, 2018, 15, 65.	2.6	14
20	Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France. BMC Health Services Research, 2018, 18, 3.	2.2	12
21	Varied exposure to carcinogenic, mutagenic, and reprotoxic (CMR) chemicals in occupational settings in France. International Archives of Occupational and Environmental Health, 2017, 90, 227-241.	2.3	25
22	Does adoption of electronic health records improve the quality of care management in France? Results from the French e-SI (PREPS-SIPS) study. International Journal of Medical Informatics, 2017, 102, 156-165.	3.3	29
23	Trends in occupational disparities for exposure to carcinogenic, mutagenic and reprotoxic chemicals in France 2003–10. European Journal of Public Health, 2017, 27, 425-432.	0.3	16
24	Does adoption of electronic health records improve organizational performances of hospital surgical units? Results from the French e-SI (PREPS-SIPS) study. International Journal of Medical Informatics, 2017, 98, 47-55.	3.3	9
25	In Reply to Escande etÂal. International Journal of Radiation Oncology Biology Physics, 2017, 97, 205-208.	0.8	1
26	Percutaneous guided biopsy for diagnosing suspected primary malignant bone tumors in pediatric patients: a safe, accurate, and cost-saving procedure. Pediatric Radiology, 2017, 47, 235-244.	2.0	22
27	Management of Febrile Neutropenias in Adolescents and Young Adults: A Cost-Minimization Analysis Between Adult Versus Pediatric Units. Journal of Adolescent and Young Adult Oncology, 2017, 6, 542-550.	1.3	0
28	Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score–Weighted Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, 929-937.	0.8	23
29	Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis. Radiotherapy and Oncology, 2016, 121, 468-474.	0.6	34
30	In Reply to Fodor and Di Muzio. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1124-1126.	0.8	2
31	COST-EFFECTIVENESS OF TREATMENTS FOR MILD-TO-MODERATE OBSTRUCTIVE SLEEP APNEA IN FRANCE. International Journal of Technology Assessment in Health Care, 2016, 32, 37-45.	0.5	18
32	Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants. Health Policy, 2016, 120, 293-305.	3.0	7
33	Cost Analysis of Complex Radiation Therapy for Patients With Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 654-662.	0.8	19
34	Development of Seasonal Influenza Vaccination Recommendations: Relevance and Influence of the Evidence on the Decision-Making Process in France and the Netherlands. Value in Health, 2016, 19, 670-679.	0.3	4
35	A Cost-Effectiveness Analysis of a 6-Month Physical Activity Program Versus Usual Dietary Care During Adjuvant Chemotherapy in Breast Cancer Patients. Value in Health, 2016, 19, A149-A150.	0.3	1
36	Impact of Electronic Health Records on the Hospital Bed Occupancy Rates in Surgical Units in France: Results from the E-SI (PREPS-SIPS) Study. Athens Journal of Health, 2016, 3, 11-26.	0.1	1

#	Article	IF	CITATIONS
37	Performance evaluation of Health Information Systems using ARIS modeling and discrete-event simulation. , $2015,  \ldots$		2
38	A literature review to identify factors that determine policies for influenza vaccination. Health Policy, 2015, 119, 697-708.	3.0	12
39	Relationship between the implementation of health information systems and the activity per surgeon and operating room usage in France: results from the E-SI (PREPS-SIPS) study. International Journal of Integrated Care, 2015, 15, .	0.2	O
40	A cost-consequence analysis of hepatitis B screening in an immigrant population. Annali Dell'Istituto Superiore Di Sanita, 2015, 51, 327-35.	0.4	0
41	Cost-Effectiveness of a Genetic Test for Breast Cancer Riskâ€"Letter. Cancer Prevention Research, 2014, 7, 475-475.	1.5	0
42	Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool. BMC Health Services Research, 2014, 14, 537.	2.2	9
43	Economic burden of seasonal influenza B in France during winter 2010-2011. BMC Public Health, 2014, 14, 56.	2.9	18
44	Cost of prostate image-guided radiation therapy: Results of a randomized trial. Radiotherapy and Oncology, 2013, 106, 50-58.	0.6	39
45	Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma. Applied Health Economics and Health Policy, 2013, 11, 129-138.	2.1	12
46	Design of a randomised controlled trial of adapted physical activity during adjuvant treatment for localised breast cancer: the PASAPAS feasibility study. BMJ Open, 2013, 3, e003855.	1.9	10
47	Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. BMC Health Services Research, 2012, 12, 82.	2.2	57
48	Transférabilité des évaluations de coûts en santé. Revue Economique, 2009, Vol. 60, 307-322.	0.3	0
49	Cost comparison of two surgical strategies in the treatment of breast cancer: Sentinel lymph node biopsy versus axillary lymph node dissection. International Journal of Technology Assessment in Health Care, 2004, 20, 449-454.	0.5	11